Loss of clock gene mPer2 promotes liver fibrosis induced by carbon tetrachloride

Hepatology Research

Volumn 40, Issue 11, 2010, Pages 1117-1127

  Chen, Peng ^a   Han, Zheyi ^b   Yang, Ping ^a   Zhu, Lin ^d   Hua, Zichun ^c   Zhang, Jianfa ^a,c  

^a NANJING UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c NANJING UNIVERSITY   (China)

^d JINLING HOSPITAL   (China)

Author keywords

Hepatic stellate cell; Liver fibrosis; mPer2

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA SMOOTH MUSCLE ACTIN; ASPARTATE AMINOTRANSFERASE; CARBON TETRACHLORIDE; COLLAGEN; COMPLEMENTARY DNA; DEATH RECEPTOR 5; MESSENGER RNA; PROTEIN MPER2; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSCRIPTION FACTOR CLOCK; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL CULTURE; CIRCADIAN RHYTHM; CONTROLLED STUDY; DISEASE SEVERITY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LIVER FIBROSIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR UPREGULATION; STELLATE CELL; WILD TYPE;

EID: 77958584111     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2010.00695.x     Document Type: Article

References (50)

1. Török NJ. Recent advances in the pathogenesis and diagnosis of liver fibrosis. J Gastroenterol 2008; 43: 315-21.
2. Prosser CC, Yen RD, Wu J. Molecular therapy for hepatic injury and fibrosis: where are we? World J Gastroenterol 2006; 12: 509-15.
3. Xia JL, Dai C, Michalopoulos GK, Liu Y. Hepatocyte growth favtor attenuates liver fibrosis induced by bile duct ligation. Am J Pathol 2006; 168: 1500-12.
4. Wang H, Zhang Y, Heuckeroth RO. PAI-1 deficiency reduces liver fibrosis after bile duct ligation in mice through activation of tPA. FEBS Lett 2007; 581: 3098-104.
5. Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 2000; 275: 2247-50.
6. Moreira RK. Hepatic stellate cells and liver fibrosis. Arch Pathol Lab Med 2007; 131: 1728-34.
7. Iwaisako K, Hatano E, Taura K et al. Loss of Sept4 exacerbates liver fibrosis through the dysregulation of hepatic stellate cells. J Hepatol 2008; 49: 768-78.
8. Krizhanovsky V, Yon M, Dickins RA et al. Senescence of activated stellate cells limits liver fibrosis. Cell 2008; 134: 657-67.
9. Yamaguchi K, Yang L, McCall S et al. Diacylglycerol acyltranferase 1 anti-sense oligonucleotides reduce hepatic fibrosis in mice with nonalcoholic steatohepatitis. Hepatology 2008; 47: 625-35.
10. Schuppan D, Ruehl M, Somasundaram R, Hahn EG. Matrix as a modulator of hepatic fibrogenesis. Semin Liver Dis 2001; 21: 351-72.
11. Rockey DC, Boyles JK, Gabbiani G, Friedman SL. Rat hepatic lipocytes express smooth muscle actin upon activation in vivo and in culture. J Submicrosc Cytol Pathol 1992; 24: 193-203.
12. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005; 115: 209-18.
13. 4-induced liver injury and fibrosis. Am J Physiol Gastrointest Liver Physiol 2007; 293: G631-9.
14. Hemmann S, Graf J, Roderfeld M, Roeb E. Expression of MMPs and TIMPs in liver fibrosis - a systematic review with special emphasis on anti-fibrotic strategies. J Hepatol 2007; 46: 955-75.
15. Iredale JP, Benyon RC, Pickering J et al. Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J Clin Invest 1998; 102: 538-49.
16. Roderfeld M, Weiskirchen R, Wagner S et al. Inhibition of hepatic fibrogenesis by matrix metalloproteinase-9 mutants in mice. FASEB J 2006; 20: 444-54.
17. Piscaglia F, Siringo S, Hermida RC et al. Diurnal changes of fibrinolysis in patients with liver cirrhosis and esophageal varices. Hepatology 2000; 31: 349-57.
18. Córdoba J, Cabrera J, Lataif L, Penev P, Zee P, Blei AT. High prevalence of sleep disturbance in cirrhosis. Hepatology 1998; 27: 339-45.
19. Schiedermaier P, Koch L, Mojón A, Hermida R, Layer G, Sauerbruch T. Circadian rhythm of fasting and postprandial portal blood flow in cirrhosis. Scand J Gastroenterol 2006; 41: 826-32.
20. Garfinkel D, Zisapel N. Liver cirrhosis and circadian rhythm. Ann Intern Med 1996; 125: 154.
21. Rutter J, Reick M, McKnight SL. Metabolism and the control of circadian rhythms. Annu Rev Biochem 2002; 71: 307-31.
22. Hastings MH, Reddy AB, Maywood ES. A clockwork web: circadian timing in brain and periphery, in health and disease. Nat Rev Neurosci 2003; 4: 649-61.
23. Kennaway DJ, Owens JA, Voultsios A, Boden MJ, Varcoe TJ. Metabolic homeostasis in mice with disrupted Clock gene expression in peripheral tissues. Am J Physiol Regul Integr Comp Physiol 2007; 293: R1528-37.
24. Ha M, Park J. Shiftwork and metabolic risk factors of cardiovascular disease. J Occup Health 2005; 47: 89-95.
25. Albrecht U, Eichele G. The mammalian circadian clock. Curr Opin Genet Dev 2003; 13: 271-7.
26. Spanagel R, Pendyala G, Abarca C et al. The clock gene Per2 influences the glutamatergic system and modulates alcohol consumption. Nat Med 2005; 11: 35-42.
27. Viswambharan H, Carvas JM, Antic V et al. Mutation of the circadian clock gene Per2 alters vascular endothelial function. Circulation 2007; 115: 2188-95.
28. Chen P, Li C, Pang W et al. The protective role of Per2 against carbon tetrachloride-induced hepatotoxicity. Am J Pathol 2009; 174: 63-70.
29. Fu L, Pelicano H, Liu J, Huang P, Lee C. The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo. Cell 2002; 111: 41-50.
30. Perugorria MJ, Latasa MU, Nicou A et al. The epidermal growth factor receptor ligand amphiregulin participates in the development of mouse liver fibrosis. Hepatology 2008; 48: 1251-61.
31. Bergqvist A, Fernö M, Skoog L. Quantitative enzyme immunoassay and semiquantitative immunohistochemistry of oestrogen and progesterone receptors in endometriotic tissue and endometrium. J Clin Pathol 1997; 50: 496-500.
32. Bergqvist A, Ljungberg O, Skoog L. Immunohistochemical analysis of oestrogen and progesterone receptors in endometriotic tissue and endometrium. Hum Reprod 1993; 8: 1915-22.
33. Moshage H. Cytokines and the hepatic acute phase response. J Pathol 1997; 181: 257-66.
34. Iredale JP. Hepatic stellate cell behavior during resolution of liver injury. Semin Liver Dis 2001; 21: 427-36.
35. Taimr P, Higuchi H, Kocova E, Rippe RA, Friedman S, Gores GJ. Activated stellate cells express the TRAIL Receptor-2/Death Receptor-5 and undergo TRAIL-mediated apoptosis. Hepatology 2003; 37: 87-95.
36. Higuchi H, Bronk SF, Takikawa Y et al. The bile acid glycochenodeoxycholate induces trail-receptor2/DR5 expression and apoptosis. J Biol Chem 2001; 276: 38610-18.
37. Meng RD, El-Deiry WS. p53-independent upregulation of KILLER/DR5 TRAIL receptor expression by glucocorticoids and interferon-gamma. Exp Cell Res 2001; 262: 154-69.
38. Sheikh MS, Burns TF, Huang Y et al. p53-dependent and -independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor alpha. Cancer Res 1998; 58: 1593-8.
39. Brown SA, Fleury-Olela F, Nagoshi E et al. The period length of fibroblast circadian gene expression varies widely among human individuals. PLoS Biol 2005; 3: e338.
40. Zheng B, Larkin DW, Albrecht U et al. The mPer2 gene encodes a functional component of the mammalian circadian clock. Nature 1999; 400: 169-73.
41. Chen P, Kakan X, Zhang J. Altered circadian rhythm of the clock genes in fibrotic livers induced by carbon tetrachloride. FEBS Lett 2010; 584: 1597-601.
42. Lyons RM, Gentry LE, Purchio AF, Moses HL. Mechanism of activation of latent recombinant transforming growth factor beta 1 by plasmin. J Cell Biol 1990; 110: 1361-7.
43. Yoshiji H, Kuriyama S, Miyamoto Y et al. Tissue inhibitor of metalloproteinases-1 promotes liver fibrosis development in a transgenic mouse model. Hepatology 2000; 32: 1248-54.
44. Yoshiji H, Kuriyama S, Yoshii J et al. Tissue inhibitor of metalloproteinases-1 attenuates spontaneous liver fibrosis resolution in the transgenic mouse. Hepatology 2002; 36: 850-60.
45. Parsons CJ, Bradford BU, Pan CQ et al. Antifibrotic effects of a tissue inhibitor of metalloproteinase-1 antibody on established liver fibrosis in rats. Hepatology 2004; 40: 1106-15.
46. Iredale JP. Tissue inhibitors of metalloproteinases in liver fibrosis. Int J Biochem Cell Biol 1997; 29: 43-54.
47. Yoshida T, Shiraishi T, Nakata S et al. Proteasome inhibitor MG132 induces death receptor 5 through CCAAT/enhancer- binding protein homologous protein. Cancer Res 2005; 65: 5662-7.
48. Lin YD, Chen S, Yue P et al. CAAT/Enhancer Binding protein homologous protein-dependent death receptor 5 induction is a major component of SHetA2-induced apoptosis in lung cancer cells. Cancer Res 2008; 68: 5335-44.
49. Kim EH, Yoon MJ, Kim SU, Kwon TK, Sohn S, Choi KS. Arsenic trioxide sensitizes human glioma cells, but not normal astrocytes, to TRAIL-induced apoptosis via CCAAT/enhancer-binding protein homologous protein-dependent DR5 up-regulation. Cancer Res 2008; 68: 266-75.
50. Sun SY, Liu X, Zou W, Yue P, Marcus AI, Khuri FR. The farnesyltransferase inhibitor lonafarnib induces CCAAT/enhancer-binding protein homologous protein-dependent expression of death receptor 5, leading to induction of apoptosis in human cancer cells. J Biol Chem 2007; 282: 18800-9.